Podcast Episodes
Back to Search
Pharmaceutical Executive Daily: Eli Lilly Acquires Engage Bio
In today's Pharmaceutical Executive Daily, Eli Lilly announces a deal worth up to $202 million for Engage Biologics and its preclinical non-viral DN…
8 hours ago
Pharmaceutical Executive Daily: TrumpRx Expands to Offer Over 600 Generic Drugs
In today’s Pharmaceutical Executive Daily, the Trump administration expands TrumpRx to include more than 600 generic medicines, industry leaders reth…
1 day, 11 hours ago
Rethinking Pharma's Go-to-Market Formula
In this episode of the Pharm Exec podcast, Mike Petroutsas, president and head of U.S. commercial at Astellas, shares the secrets to building a more…
1 day, 12 hours ago
Pharmaceutical Executive Daily: FDA Approves Baxdrostat
2 days, 10 hours ago
Pharmaceutical Executive Daily: FDA Approves AstraZeneca's Fasenra
In today's Pharmaceutical Executive Daily, FDA approves AstraZeneca's Fasenra as a new treatment for hypereosinophilic syndrome in patients 12 years …
5 days, 10 hours ago
Pharmaceutical Executive Daily: FDA Approves Beqalzi and Inqovi
In today's Pharmaceutical Executive Daily, the FDA grants accelerated approval to BeOne Medicines' Beqalzi as the first and only BCL2 inhibitor for r…
6 days, 9 hours ago
Pharmaceutical Executive Daily: Rigel Pharmaceuticals Enters an Exclusive Global Licensing Agreement with Arvinas and Pfizer for Veppanu
In today's Pharmaceutical Executive Daily, Rigel Pharmaceuticals enters an exclusive global licensing agreement with Arvinas and Pfizer for Veppanu, …
1 week ago
Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen
In today's Pharmaceutical Executive Daily, GSK enters an exclusive collaboration with Sino Biopharmaceutical's CTTQ subsidiary to accelerate the laun…
1 week, 2 days ago
Pharmaceutical Executive Daily: FDA Extends Review of Leqembi's sBLA
In today’s Pharmaceutical Executive Daily, the FDA extends its priority review of a subcutaneous formulation of Leqembi, industry analysts examine ho…
1 week, 5 days ago
Pharmaceutical Executive Daily: Angelini Pharma Acquires Catalyst Pharmaceuticals in $4.1 Billion Agreement
In today's Pharmaceutical Executive Daily, Angelini Pharma announces a $4.1 billion agreement to acquire Catalyst Pharmaceuticals, Incyte presents 24…
1 week, 6 days ago